Healthcare Revenue Cycle and Finance

The Pain, Confusion, and Costs of Prior Authorization

By Deanne Kasim – With the increase in specialty drugs, innovative diagnostic testing, and precision medicine, it is expected that the use of the Prior Authorization will only increase with health insurance companies. Of course I have heard from many re: the (theoretical) fact that as the use of value-based provider reimbursement matures, there will be less and less need for a PA process.

Read More

How Do We Level the HIT Playing Field?

By Roger Davis – “We are deadly serious about interoperability.” – Andy Slavitt, Acting Administrator of the CMS at the J. P. Morgan Healthcare Conference in San Francisco in January 2016. For those of us in the healthcare vendor community, that defining statement sets the tone for the future interaction between organizations.